Incidence and impact of activating mutations of the RAS-RAF- MEK-ERK pathway in patients with philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative disorders-unclassified (MDS/MPD-U)

Santos, Fabio P. S.Lisboa, BiancaDatoguia, Tarcila S.Helman, RicardoPereira, Welbert OliveiraPuga, Renato D.Miyagi, MarianaMata, Evelyn H. A. daSantucci, RodrigoPerini, Guilherme F.Souto, Eizabeth XistoKassab, CarolinaPadua, LeandroBollman, Patricia W.Higashi, MarciaSoares, RodolfoFadel, Adriana Valente [UNESP]Musacchio, JulianeSchriefer, Ana FernandesSalvino, Marco AurelioCordeiro De Farias, Danielle LeaoPerobelli, Leila MartinsCosta, Erika M. M.Lima, Marinus M.Mattos, Vinicius R. P.Silveira, Paulo A. A.Bacal, NydiaGuerra, Joao CarlosBezerra, Alanna Mara P. S.Pasqualin, Denise da CunhaBello, Isabel C.Diniz, Michelli SilvaNakashima, Sandra S.Velloso, ElviraHamerschlak, NelsonCampregher, Paulo Vidal2015-11-032015-11-032014-12-06Blood. Washington: Amer Soc Hematology, v. 124, n. 21, p. 1-4, 2014.0006-4971http://hdl.handle.net/11449/1303441-4engIncidence and impact of activating mutations of the RAS-RAF- MEK-ERK pathway in patients with philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative disorders-unclassified (MDS/MPD-U)ResumoWOS:000349243503205Acesso aberto